Enterprise Value
-135.6M
Cash
595.7M
Avg Qtr Burn
-40.69M
Short % of Float
13.05%
Insider Ownership
15.72%
Institutional Own.
68.50%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LYL845 Details Solid tumor/s, Cancer, Colorectal cancer , Non-small cell lung carcinoma, Melanoma | Phase 1 Data readout | |
LYL797 Details Solid tumor/s, Cancer, Non-small cell lung carcinoma, Breast cancer | Phase 1 Data readout |